长药控股(300391) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was ¥27,350,578.70, a decrease of 94.99% compared to the same period last year[2] - The net profit attributable to shareholders for Q3 2024 was -¥28,397,667.92, representing a 69.01% increase in losses year-over-year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥28,448,505.13, a 68.89% increase in losses compared to the previous year[2] - Total operating revenue for Q3 2024 was CNY 101,004,271.66, a decrease of 90.1% compared to CNY 1,021,867,556.56 in the same period last year[13] - Net loss for Q3 2024 was CNY 280,105,175.88, compared to a net loss of CNY 137,591,259.61 in Q3 2023[14] - Basic and diluted earnings per share for Q3 2024 were -0.5166, compared to -0.3307 in the same period last year[15] Assets and Liabilities - Total assets at the end of Q3 2024 were ¥3,091,124,027.79, down 10.29% from the end of the previous year[2] - The company's total assets decreased to CNY 3,091,124,027.79 from CNY 3,445,757,061.65 in the previous year[12] - Total liabilities decreased to CNY 2,353,907,774.13 from CNY 2,428,435,632.11 year-over-year[12] - The equity attributable to shareholders at the end of Q3 2024 was ¥14,150,342.30, a decrease of 92.75% compared to the end of the previous year[2] - The total equity attributable to shareholders of the parent company was CNY 14,150,342.30, down from CNY 195,121,069.29 year-over-year[12] Cash Flow - The net cash flow from operating activities was -¥32,743,232.81, a decrease of 202.52% compared to the same period last year[6] - Cash inflow from operating activities totaled ¥110,049,012.76, a decrease of 88.8% from ¥982,449,181.56 in the previous year[16] - Cash outflow from operating activities was ¥142,792,245.57, leading to a net cash flow from operating activities of -¥32,743,232.81, compared to ¥31,937,006.16 last year[16] - Cash flow from investing activities resulted in a net outflow of -¥11,147,495.91, down from a net inflow of ¥23,595,406.74 in the previous year[17] - Cash inflow from financing activities was ¥130,686,280.12, an increase of 57% from ¥83,151,645.33 last year[17] - Net cash flow from financing activities was ¥41,250,705.59, compared to -¥63,524,995.96 in the same period last year[17] - The ending balance of cash and cash equivalents was ¥3,681,317.52, down from ¥6,568,862.86 at the end of the previous year[17] - The company’s total cash and cash equivalents decreased by ¥2,619,794.32 during the quarter[17] Shareholder Information - The company had a total of 22,151 common shareholders at the end of the reporting period[7] - The report indicates that the company is actively managing its shareholder structure, with significant changes in the top 10 shareholders[8] Operational Insights - The company reported a significant decrease in operating income primarily due to reduced revenue in the pharmaceutical sector[6] - The company experienced a 1815.10% increase in estimated liabilities, mainly due to litigation provisions[6] - The company is focusing on market expansion and new product development, although specific figures were not disclosed in the report[10] - The company has not disclosed any new mergers or acquisitions in this quarter's report[10] Current Assets - Total current assets decreased from CNY 2,128,624,939.48 at the beginning of the period to CNY 1,824,034,910.75 at the end of the period, representing a decline of approximately 14.3%[10] - Cash and cash equivalents dropped significantly from CNY 15,203,300.56 to CNY 6,736,442.47, a decrease of about 55.7%[10] - Accounts receivable decreased from CNY 1,639,156,949.32 to CNY 1,521,898,918.72, reflecting a reduction of approximately 7.2%[10] - Inventory also saw a decline from CNY 51,858,189.15 to CNY 45,420,832.36, which is a decrease of around 12.8%[10] - Non-current assets, specifically fixed assets, decreased from CNY 763,856,572.40 to CNY 741,810,585.73, indicating a decline of about 2.9%[10] - The company reported a total of CNY 126,690,564.00 in prepayments, which increased from CNY 120,759,307.99, showing a growth of approximately 4.9%[10] - The company has a total of CNY 73,937,024.55 in other receivables, down from CNY 243,940,881.13, a significant decrease of about 69.7%[10] Research and Development - Research and development expenses for Q3 2024 were CNY 3,328,745.66, down from CNY 6,136,499.43 in the same period last year[13] - The company reported a significant increase in financial expenses, totaling CNY 63,064,422.22 compared to CNY 57,380,083.49 in the previous year[13] - The company's goodwill decreased from CNY 236,069,896.40 to CNY 208,626,653.90[12]